Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Shares in pharmaceuticals group Novo Nordisk (NVO) remained in good shape today despite reports that its weight loss drugs ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...